Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynAct Pharma ABOSTO:SYNACT -1.64%27 EV-to-EBITDA is -8.46 as of Aug. 07, 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 409 Biotechnology companies, SynAct Pharma AB ranks worse than 244498.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SynAct Pharma AB's enterprise value is kr1,007.09 Mil.
SynAct Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-119.00 Mil. Therefore, SynAct Pharma AB's EV-to-EBITDA for today is -8.46.
The historical rank and industry rank for SynAct Pharma AB's EV-to-EBITDA or its related term are showing as below:
OSTO:SYNACT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.62 Med: 0 Max: 0
Current: -8.47
OSTO:SYNACT's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs OSTO:SYNACT: -8.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SynAct Pharma AB (OSTO:SYNACT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SynAct Pharma AB's PE Ratio (TTM) for today is calculated as:
SynAct Pharma AB's share price for today is kr19.14.
SynAct Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-49.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SynAct Pharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SYNACT vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, SynAct Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynAct Pharma AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SynAct Pharma AB's EV-to-EBITDA falls into.
SynAct Pharma AB's current Enterprise Value is kr1,007.09 Mil.
SynAct Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-119.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynAct Pharma AB (OSTO:SYNACT) has a EV-to-EBITDA of -8.46 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SynAct Pharma AB. According to the industry distribution chart, SynAct Pharma AB ranks #999999 out of 409 companies in the Biotechnology industry.
Is SynAct Pharma AB's EV-to-EBITDA too high?
SynAct Pharma AB's current EV-to-EBITDA is -8.46. Based on the distribution chart, SynAct Pharma AB ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SynAct Pharma AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SynAct Pharma AB ranks #999999 out of 409 companies for EV-to-EBITDA. This places SynAct Pharma AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SynAct Pharma AB. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SynAct Pharma AB's current EV-to-EBITDA is -8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current EV-to-EBITDA of -8.46. The current EV-to-EBITDA is -8.46. SynAct Pharma AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current EV-to-EBITDA is -8.46 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
27GF Score
Get the complete analysis for OSTO:SYNACT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SYNACT has been successfully added to your 
